Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Akebia Therapeutics, Inc. AKBA |
BLACKROCK INC BLK |
15,141,768 6.100% |
-55,439 (-0.36%) |
Filing History |
| 2025-02-14 5:00 pm Sale |
2024-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
Satter Muneer A | 5,747,906 2.600% |
-10,457,213 (-64.53%) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Akebia Therapeutics, Inc. AKBA |
BLACKROCK INC BLK |
15,197,207 7.200% |
0 (Unchanged) |
Filing History |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | Akebia Therapeutics, Inc. AKBA |
BLACKROCK INC BLK |
15,197,207 7.200% |
10,857,181 (+250.16%) |
Filing History |
| 2024-02-13 4:58 pm Sale |
2023-12-29 | 13G | Akebia Therapeutics, Inc. AKBA |
The Vanguard Group | 7,607,472 4.040% |
-3,631,398 (-32.31%) |
Filing History |
| 2024-02-09 4:00 pm Purchase |
2023-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
Satter Muneer A | 16,205,119 8.600% |
1,115,000 (+7.39%) |
Filing History |
| 2023-02-10 1:08 pm Purchase |
2022-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
Satter Muneer A | 15,090,119 8.200% |
1,225,789 (+8.84%) |
Filing History |
| 2023-02-09 10:54 am Sale |
2022-12-30 | 13G | Akebia Therapeutics, Inc. AKBA |
The Vanguard Group | 11,238,870 6.110% |
-7,120,550 (-38.78%) |
Filing History |
| 2023-01-20 08:55 am Sale |
2022-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
STATE STREET CORP STT |
571,936 0.310% |
-11,171,525 (-95.13%) |
Filing History |
| 2022-12-19 4:10 pm Purchase |
2022-12-08 | 13G | Akebia Therapeutics, Inc. AKBA |
Satter Muneer A | 13,864,330 7.500% |
10,797,287 (+352.04%) |
Filing History |
| 2022-07-08 4:56 pm Sale |
2022-06-30 | 13G | Akebia Therapeutics, Inc. AKBA |
BLACKROCK INC BLK |
4,340,026 2.400% |
-9,784,189 (-69.27%) |
Filing History |
| 2022-06-09 2:15 pm Purchase |
2022-05-31 | 13G | Akebia Therapeutics, Inc. AKBA |
The Vanguard Group | 18,359,420 10.000% |
5,123,751 (+38.71%) |
Filing History |
| 2022-02-10 1:23 pm Sale |
2021-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
STATE STREET CORP STT |
11,743,461 6.710% |
-2,263,176 (-16.16%) |
Filing History |
| 2022-02-09 3:16 pm Purchase |
2021-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
The Vanguard Group | 13,235,669 7.560% |
4,800,910 (+56.92%) |
Filing History |
| 2022-02-07 4:41 pm Purchase |
2021-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
BLACKROCK INC BLK |
14,124,215 8.100% |
2,726,667 (+23.92%) |
Filing History |
| 2021-08-10 07:57 am Sale |
2021-07-30 | 13G | Akebia Therapeutics, Inc. AKBA |
WELLINGTON MANAGEMENT CO LLP | 711 0.000% |
-12,589,752 (-99.99%) |
Filing History |
| 2021-07-12 10:45 am Sale |
2021-06-30 | 13G | Akebia Therapeutics, Inc. AKBA |
STATE STREET CORP STT |
14,006,637 8.750% |
-8,469,897 (-37.68%) |
Filing History |
| 2021-02-12 06:42 am Purchase |
2020-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
Nantahala Capital Management, LLC | 7,040,487 4.900% |
303,367 (+4.50%) |
Filing History |
| 2021-02-11 12:43 pm Sale |
2020-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
STATE STREET CORP STT |
22,476,534 15.550% |
-340,636 (-1.49%) |
Filing History |
| 2021-02-10 10:30 am Purchase |
2020-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
The Vanguard Group | 8,434,759 5.840% |
8,434,759 (New Position) |
Filing History |